Literature DB >> 10865159

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

P W Stone1, S Teutsch, R H Chapman, C Bell, S J Goldie, P J Neumann.   

Abstract

BACKGROUND: Cost-effectiveness analyses of clinical preventive services are a potential means to aid public health resource allocation. Cost-utility analysis (CUA) is a specific form of cost-effectiveness analysis where results are expressed in terms of cost per quality-adjusted life year (QALY) gained. To increase the transparency and comparability of CUAs, standardization of methods has been recommended.
OBJECTIVES: The purposes of this study were as follows: (1) identify published articles with original CUAs of primary and secondary clinical preventive services, (2) summarize the ratios found in these analyses, (3) identify articles employing comparable methods, and (4) explore analytic methods employed over time.
METHODS: As part of a larger study we conducted a comprehensive search of published CUAs in the area of clinical preventive services and systematically collected data on the results of the analyses and analytic methods employed. Cost-effectiveness ratios were standardized and organized into a table.
RESULTS: We found 50 CUAs pertaining to clinical preventive services (primary, n=22, 44%; and secondary, n=28, 56%) and 174 cost-effectiveness ratios. These ratios ranged from cost-savings up to $27,000,000/QALY, with a median of $14,000/QALY. Only three (6%) of the CUAs met minimum reference case requirements. There was no apparent improvement of methods over time.
CONCLUSIONS: Immunizations and chemoprophylaxis have the most favorable cost-effectiveness ratios, and preventive services are more cost-effective when targeted at high-risk populations. However, there is wide variation in the methods used in these analyses. This study allows us to define where improvements in methodologic rigor need to occur, provides a base-line for future audits, and highlights disease areas in clinical preventive services that have been omitted or underevaluated.

Mesh:

Year:  2000        PMID: 10865159     DOI: 10.1016/s0749-3797(00)00151-3

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  18 in total

1.  Is an ounce of prevention always worth a pound of cure? Yes: clinical preventive services can provide excellent value.

Authors:  S M Teutsch
Journal:  West J Med       Date:  2001-02

2.  [Economic aspects of prevention].

Authors:  H H König; S Riedel-Heller
Journal:  Internist (Berl)       Date:  2008-02       Impact factor: 0.743

3.  Measuring the value of public health systems: the disconnect between health economists and public health practitioners.

Authors:  Peter J Neumann; Peter D Jacobson; Jennifer A Palmer
Journal:  Am J Public Health       Date:  2008-10-15       Impact factor: 9.308

4.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

5.  30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

Authors:  Peter J Neumann; Chi-Hui Fang; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 6.  Economic evaluation of drug abuse treatment and HIV prevention programs in pregnant women: a systematic review.

Authors:  Jennifer Prah Ruger; Christina M Lazar
Journal:  Addict Behav       Date:  2011-08-05       Impact factor: 3.913

7.  Cost-effective osteoporosis treatment thresholds: the United States perspective.

Authors:  A N A Tosteson; L J Melton; B Dawson-Hughes; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 8.  Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.

Authors:  Jennifer Prah Ruger; Karen M Emmons
Journal:  Value Health       Date:  2007-09-13       Impact factor: 5.725

Review 9.  Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US.

Authors:  Joseph A Ladapo; Peter J Neumann; Ron Keren; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 10.  A review of economic evaluations of tobacco control programs.

Authors:  Jennifer W Kahende; Brett R Loomis; Bishwa Adhikari; Latisha Marshall
Journal:  Int J Environ Res Public Health       Date:  2008-12-28       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.